Oritavancin

證據等級: L5

預測適應症: 3 個

Oritavancin: Predicted New Indication — Bacteroidaceae Infectious Disease

One-Sentence Summary

Oritavancin's original approved indication is not documented in the current data pack (data gap). The TxGNN model's top prediction for this drug is Bacteroidaceae infectious disease, with a score of 99.48%, but 0 clinical trials and 0 publications currently support this direction, and the drug's own mechanism of action directly contradicts the prediction.

Quick Overview

Item	Content
Original Indication	Not documented in available data (data gap)
Predicted New Indication	Bacteroidaceae infectious disease
TxGNN Prediction Score	99.48%
Evidence Level	L5
Finland Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed original-indication and formal MOA data are not available for oritavancin in this evidence pack (flagged as a High-severity data gap). Based on the mechanistic notes attached to the prediction itself, oritavancin is a lipoglycopeptide antibiotic that inhibits bacterial peptidoglycan transglycosylation/transpeptidation and disrupts cell membrane integrity — a mechanism active only against Gram-positive organisms (including MRSA and VRE).

This mechanism does not support the top prediction. Bacteroidaceae are Gram-negative anaerobes whose outer membrane blocks glycopeptide penetration to the target site — glycopeptides are pharmacologically known to be ineffective against Gram-negative bacteria. The prediction therefore conflicts directly with established pharmacology despite its high TxGNN score.

The same pattern holds for the two next-ranked candidates in this evidence pack: ophthalmic herpes zoster (rank 2, score 99.03%) is caused by a virus (VZV), for which a cell-wall-targeting antibacterial has no plausible mechanism; and Mycoplasma pneumoniae pneumonia (rank 3, score 99.01%) involves a pathogen that entirely lacks a cell wall, the sole known target of oritavancin. All three top predictions for this drug are flagged internally as mechanistically unsupported, which is an important caveat when interpreting the raw TxGNN scores.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Finland Market Information

Oritavancin is not currently marketed in Finland; no authorization records are available (0 licenses on file).

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN prediction score (99.48%), the repurposing rationale attached to this candidate explicitly identifies a mechanistic contradiction — glycopeptide antibiotics are not active against the Gram-negative anaerobic target — and there is zero supporting real-world evidence (no clinical trials, no literature). The two next-ranked candidates for this drug show the same pattern (viral etiology and cell-wall-deficient pathogen, respectively, both incompatible with the drug's cell-wall-targeting mechanism), and safety data (warnings, contraindications, DDI) is a Blocking data gap that prevents any S1 safety screening.

To proceed, the following is needed:

TFDA/Fimea package insert data (warnings, contraindications) — currently Blocking gap (DG001)
Confirmed original indication and formal MOA documentation — currently High-severity gap (DG002)
Independent pharmacological review reconciling the TxGNN score with the mechanistic contradiction before any further evaluation
DDI/safety database query (current status: not found)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.